Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

IBRX – ImmunityBio, Inc.

Float Short %

78.38

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

-0.02

EPS Last/This Y

0.11

EPS This/Next Y

0.18

Price

2.31

Target Price

10.2

Analyst Recom

1

Performance Q

-13.81

Relative Volume

1.09

Beta

0.18

Ticker: IBRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25IBRX2.860.270.13222722
2025-07-28IBRX2.650.280.91223818
2025-07-29IBRX2.550.280.26226902
2025-07-30IBRX2.560.290.45227515
2025-07-31IBRX2.450.290.41228101
2025-08-01IBRX2.360.290.73229716
2025-08-04IBRX2.40.290.44230274
2025-08-05IBRX2.40.290.39231707
2025-08-06IBRX2.380.290.13232451
2025-08-07IBRX2.40.290.24233663
2025-08-08IBRX2.430.290.40234171
2025-08-11IBRX2.460.300.48237320
2025-08-12IBRX2.460.300.09241613
2025-08-13IBRX2.820.300.09241826
2025-08-14IBRX2.70.270.35264501
2025-08-15IBRX2.540.270.10264724
2025-08-18IBRX2.420.250.16217023
2025-08-19IBRX2.280.250.24223298
2025-08-20IBRX2.260.250.36227668
2025-08-21IBRX2.230.260.41229209
2025-08-22IBRX2.310.260.04230173
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25IBRX2.86- 23.6-0.49
2025-07-28IBRX2.66- 28.1-0.49
2025-07-29IBRX2.54- 21.6-0.48
2025-07-30IBRX2.56- 2.9-0.48
2025-07-31IBRX2.46- 13.7-0.48
2025-08-01IBRX2.37- 13.2-0.48
2025-08-04IBRX2.41- 1.0-0.48
2025-08-05IBRX2.41- 5.3-0.48
2025-08-06IBRX2.3812.515.0-0.48
2025-08-07IBRX2.4012.5-16.7-0.48
2025-08-08IBRX2.440.0-26.5-0.51
2025-08-11IBRX2.460.0-25.0-0.51
2025-08-12IBRX2.4712.5-22.5-0.47
2025-08-13IBRX2.8212.5-56.8-0.47
2025-08-14IBRX2.7112.5-13.6-0.47
2025-08-15IBRX2.5412.5-7.9-0.47
2025-08-18IBRX2.4212.5-11.3-0.47
2025-08-19IBRX2.2812.5-8.3-0.47
2025-08-20IBRX2.2612.5-20.5-0.47
2025-08-21IBRX2.2312.5-20.5-0.47
2025-08-22IBRX2.3112.5-29.9-0.47
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25IBRX0.0053.5083.84
2025-07-28IBRX0.0054.1683.84
2025-07-29IBRX0.0054.1683.84
2025-07-30IBRX0.0054.1683.84
2025-07-31IBRX0.0054.1681.12
2025-08-01IBRX0.0054.1681.12
2025-08-04IBRX0.0054.8681.12
2025-08-05IBRX0.0054.8681.12
2025-08-06IBRX0.0054.8681.12
2025-08-07IBRX0.0054.8681.12
2025-08-08IBRX0.0054.8678.29
2025-08-11IBRX0.0049.4878.29
2025-08-12IBRX0.0049.4878.38
2025-08-13IBRX0.0049.4878.38
2025-08-14IBRX0.0049.4878.38
2025-08-15IBRX0.0049.4878.38
2025-08-18IBRX0.0046.8778.38
2025-08-19IBRX0.0046.8778.38
2025-08-20IBRX0.0046.8778.38
2025-08-21IBRX0.0046.8778.38
2025-08-22IBRX0.0046.8778.38
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.1

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

46.87

Beta

0.18

Average Sales Estimate Current Quarter

31

Average Sales Estimate Next Quarter

35

Fair Value

Quality Score

72

Growth Score

56

Sentiment Score

1

Actual DrawDown %

94.4

Max Drawdown 5-Year %

Target Price

10.2

P/E

Forward P/E

PEG

P/S

38.58

P/B

P/Free Cash Flow

EPS

-0.49

Average EPS Est. Cur. Y​

-0.47

EPS Next Y. (Est.)

-0.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-648.57

Relative Volume

1.09

Return on Equity vs Sector %

39.6

Return on Equity vs Industry %

52.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-29.9
ImmunityBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 685
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today
news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance
stock history IBRX – ImmunityBio, Inc. invest stock market
stock prices IBRX premarket after hours
ticker IBRX fair value insiders trading